BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, December 24, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 15, 2014

View Archived Issues

Phase II results for field-mixed avian influenza A/H7N9 vaccine with MF59 adjuvant

Read More

RAPID-PsA phase III results for certolizumab pegol in patients with active psoriasis

Read More

Stada Arzneimittel in-licenses teriparatide biosimilar

Read More

Identification of a novel druggable target for the development of new anxiolytics

Read More

Rigontec in first closing of Series A financing

Read More

Promising results presented for the novel EGFR tyrosine kinase inhibitor, AZD-9291

Read More

GAPVAC consortium advances a personalized cancer vaccine approach into the clinic for glioblastoma

Read More

In vitro inhibition of Middle East respiratory syndrome coronavirus with BanLec

Read More

Cutaneous tolerability and therapeutic benefits of LAS-41010

Read More

Phase I data for MPDL-3280A for the treatment of UBC and other malignancies

Read More

Researchers at Merck & Co. disclose new agents for Alzheimer's disease

Read More

A team of scientists at Amgen synthesizes novel protease inhibitors

Read More

Merck Sharp & Dohme designs new tyrosine-protein kinase inhibitors

Read More

Researchers at Roche present novel A-FABP inhibitors

Read More

Seragon Pharmaceuticals designs novel ER-alpha ligands for cancer and other disorders

Read More

GW Pharmaceuticals reports topline results from the phase IIa GWP-42003 trial

Read More

Aethlon Medical uses Hemopurifier blood filtration device in patient with Ebola virus infection

Read More

Raze Therapeutics formed to target mitochondrial one-carbon metabolism in cancer cells

Read More

Mochida and LG Life Sciences enter adalimumab biosimilar agreement

Read More

MRC Technology and Proximagen collaborate in inflammatory and autoimmune diseases

Read More

FDA grants olaratumab orphan drug status for soft tissue sarcoma

Read More

Resimmune receives orphan designation for cutaneous T-cell lymphoma in the U.S.

Read More

FDA grants priority review to rufinamide sNDA

Read More

FDA approves Quidel's Lyra Adenovirus Assay

Read More

Sorrento Therapeutics plans to reduce sample size in Cynviloq bioequivalence study

Read More

Zenith Epigenetics suspends development of ZEN-3365

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing